VPC
TEVA icon

Vestal Point Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Vestal Point Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200,000
Closed -$2.09M – 74
2023
Q4 		$2.09M Buy
+200,000
New +$1.87M 0.22% 37

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vestal Point Capital's TEVA Position: Q1 2024 in Review

Vestal Point Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 200,000 shares — an estimated $2.09M sold.

Vestal Point Capital first reported a position in TEVA in Q4 2023 and held it in 1 quarter. The position peaked at $2.09M in Q4 2023. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Vestal Point Capital reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Vestal Point Capital sold 200,000 Teva Pharmaceuticals shares in Q1 2024, an estimated $2.09M.
  • Vestal Point Capital first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Vestal Point Capital's Teva Pharmaceuticals position peaked at $2.09M in Q4 2023.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.